InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,735.76
(
0.53%
)
US TECH 100
19,538.00
(
0.95%
)
Dow Jones
42,055.51
(
0.70%
)
Brent Oil
73.22
(
-1.07%
)
Bitcoin
69,631.10
(
-0.82%
)
Post# of 253509
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120655
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: laker9029 post# 103576

Tuesday, 09/07/2010 8:14:36 AM

Tuesday, September 07, 2010 8:14:36 AM

Post# of 253509

It appears that this was a high-risk action that could have been avoided. What was the reasoning for doing this particular trial (2 unapproved drugs) at this point in time?

All-oral regimens are the future of HCV therapy. The drug-drug-interaction study of IDX184+IDX320 in healthy volunteers was a prerequisite for running a combination trial in HCV patients.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up